| abstract |
A neublastin variant having increased bioavailability is identified. Disclosed are variant neublastin polypeptides suitable for formation of a conjugate comprising a variant neublastin polypeptide linked to a polymer comprising a polyalkylene glycol moiety. The conjugate has long-term bioavailability and, in preferred embodiments, has long-term biological activity compared to the unmodified form of neublastin or the wild-type form of neublastin. The conjugates of the invention are typically usefully used in therapeutic and non-therapeutic applications (eg diagnostic applications). [Selection figure] None |